Safety and Efficacy of Sparsentan Versus Irbesartan in Focal Segmental Glomerulosclerosis and IgA Nephropathy: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2024 Sep 28

PMID 39333921

Authors

Ahmed A Abo Elnaga

Mohamed A Alsaied

Abdelrahman M Elettreby

Alaa Ramadan

Mohamed Abouzid

Raghda Shetta

Yazan A Al-Ajlouni

Affiliations

Soon will be listed here.

Abstract

Background: Sparsentan has shown positive effects on managing different subtypes of glomerulonephritis. The recent results of trials require a pooled analysis to validate these results.

Aim: We aim to assess the safety and efficacy of sparsentan versus irbesartan for patients with IgA nephropathy and focal glomerulosclerosis (FSGS).

Methods: We conducted a systematic review and meta-analysis of randomized controlled trials retrieved by systematically searching PubMed, Web of Science, Scopus, and Cochrane through March 2024. We used Review Manager v.5.4 to pool dichotomous data using risk ratio (RR) and continuous data using mean difference (MD) with a 95% confidence interval (CI).

Results: Three studies with a total of 884 patients were included. Sparsentan was superior to irbesartan in improving urine protein to creatinine ratio (UP/C) (ratio of percentage reduction 0.66, 95% CI [0.58 to 0.74], P < 0.001); as well as the proportion of patients achieved complete and partial remission of proteinuria (RR = 2.57, 95% CI [1.73 to 3.81], P < 0.001) and (RR = 1.63, 95% CI [1.4 to 1.91], P < 0.001) respectively. Regarding the effect on the glomerular filtration rate, the results estimate did not favor either sparsentan or irbesartan (MD = 1.98 ml/min per 1.73mm2, 95% CI [-1.05 to 5.01], P = 0.2). There were no significant differences in adverse events except for hypotension, which showed higher rates in the sparsentan group (RR = 2.02, 95% CI [1.3 to 3.16], P = 0.002).

Conclusion: Sparsentan is effective and has a good safety profile for treating FSGS and patients with IgA nephropathy. However, more well-designed RCTs against ARBs, ACE inhibitors, and steroids with larger sample sizes are needed to get conclusive evidence.

References

de Cos M, Meliambro K, Campbell K . Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis. Kidney Int Rep. 2023; 8(1):30-35. PMC: 9831941. DOI: 10.1016/j.ekir.2022.10.004. View

Kwon C, Daniele P, Forsythe A, Ngai C . A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy. J Health Econ Outcomes Res. 2021; 8(2):36-45. PMC: 8410133. DOI: 10.36469/001c.26129. View

Schena F, Nistor I . Epidemiology of IgA Nephropathy: A Global Perspective. Semin Nephrol. 2018; 38(5):435-442. DOI: 10.1016/j.semnephrol.2018.05.013. View

Kiffel J, Rahimzada Y, Trachtman H . Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis. 2011; 18(5):332-8. PMC: 3709971. DOI: 10.1053/j.ackd.2011.03.005. View

Wetmore J, Guo H, Liu J, Collins A, Gilbertson D . The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis. Kidney Int. 2016; 90(4):853-60. DOI: 10.1016/j.kint.2016.04.026. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100(4S):S1-S276. DOI: 10.1016/j.kint.2021.05.021. View

Stefan G, Zugravu A, Stancu S . Mortality in IgA Nephropathy: A Long-Term Follow-Up of an Eastern European Cohort. Medicina (Kaunas). 2024; 60(2). PMC: 10890558. DOI: 10.3390/medicina60020247. View

Pattrapornpisut P, Avila-Casado C, Reich H . IgA Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021; 78(3):429-441. DOI: 10.1053/j.ajkd.2021.01.024. View

10.

Morphy R, Rankovic Z . Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005; 48(21):6523-43. DOI: 10.1021/jm058225d. View

11.

De Vriese A, Wetzels J, Glassock R, Sethi S, Fervenza F . Therapeutic trials in adult FSGS: lessons learned and the road forward. Nat Rev Nephrol. 2021; 17(9):619-630. PMC: 8136112. DOI: 10.1038/s41581-021-00427-1. View

12.

Trachtman H, Nelson P, Adler S, Campbell K, Chaudhuri A, Derebail V . DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol. 2018; 29(11):2745-2754. PMC: 6218860. DOI: 10.1681/ASN.2018010091. View

13.

Rheault M, Alpers C, Barratt J, Bieler S, Canetta P, Chae D . Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 2023; 389(26):2436-2445. DOI: 10.1056/NEJMoa2308550. View

14.

Inker L, Collier W, Greene T, Miao S, Chaudhari J, Appel G . A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023; 29(7):1867-1876. DOI: 10.1038/s41591-023-02418-0. View

15.

Konigshausen E, Sellin L . Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates. Biomed Res Int. 2016; 2016:3765608. PMC: 4856884. DOI: 10.1155/2016/3765608. View

16.

Rovin B, Barratt J, Heerspink H, Alpers C, Bieler S, Chae D . Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023; 402(10417):2077-2090. DOI: 10.1016/S0140-6736(23)02302-4. View

17.

Thompson A, Carroll K, Inker L, Floege J, Perkovic V, Boyer-Suavet S . Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019; 14(3):469-481. PMC: 6419287. DOI: 10.2215/CJN.08600718. View

18.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

19.

Trachtman H, Komers R, Inrig J . Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy. Expert Rev Clin Immunol. 2024; 20(6):571-576. DOI: 10.1080/1744666X.2024.2319132. View

20.

Lenoir O, Milon M, Virsolvy A, Henique C, Schmitt A, Masse J . Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol. 2014; 25(5):1050-62. PMC: 4005294. DOI: 10.1681/ASN.2013020195. View